About Cycle Pharma
Cycle Pharma is a Healthcare company based in Cambridge (United Kingdom) founded in 2012. Small molecule drugs are reformulated and repurposed for orphan indications. The company has 54 employees. Cycle Pharma has completed 2 acquisitions, including Applied Therapeutics and Banner Life Sciences. Cycle Pharma offers products and services including Cycle Vita and VENXXIVA. Its focus areas include Life Sciences, Rare Diseases, Drugs and Metabolic Disorders. Its legal entity is CYCLE PHARMACEUTICALS LTD.
Company details
Cycle Pharma was founded in 2012 and is based in Cambridge, United Kingdom. Operations focus on biopharmaceutical development, including reformulation and repurposing of small molecule drugs for orphan diseases. FDA approval was granted in August 2017 for NITYR (nitisinone tablets), used to treat Hereditary Tyrosinemia type 1, with a formulation that avoids refrigeration and allows dissolution in water for pediatric use. Generics are also manufactured by the company.
- Headquarters Cambridge, United Kingdom
- Employees 54
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website cyclepharma.com
- Social LinkedIn X Facebook
- Legal Name Cycle Pharmaceuticals Ltd
- Date of Incorporation 02 Feb, 2012
- Jurisdiction CAMBRIDGE, ENGLAND
- Annual Revenue$30.23 M (USD)31as on Dec 31, 2020
- Net Profit$10.71 M (USD)67as on Dec 31, 2020
- Latest Funding Round$25M (USD), Debt – Conventional
Sep 2020
- Investors
- Employee Count54
- Investments & AcquisitionsApplied Therapeutics
& 1 more
Products & Services of Cycle Pharma
Cycle Pharma offers a comprehensive portfolio of products and services, including Cycle Vita and VENXXIVA.
AI-powered app for managing rare diseases like PKU.
Tablets for treating cystinuria and reducing pill burden.
Funding Insights of Cycle Pharma
- Total Rounds 1
- Last Round Debt – Conventional — $25M
- First Round $25M
(Sep 2020)
- Investors Count 1
All 1 funding rounds of Cycle Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | $25M | Debt – Conventional | – | – |
1 investors in total: 1 institutional.
Investors in Cycle Pharma
Cycle Pharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Deutsche Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified banking and financial services are provided globally. | 1870 | db.com | Frankfurt Am Main, Germany |
Investor details for Cycle Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cycle Pharma
34 people are tracked at Cycle Pharma (12 in leadership, 6 in board & advisors, 16 in team); the tracked headcount is 54.
| Name | Role | Group |
|---|---|---|
David R. | Director Of Sales, Hematology & Oncology | Leadership |
Damien Sango | Director, Market Access And Distribution | Leadership |
Zac Bohlen | VP, US Sales | Leadership |
Catherine Wainwright | Senior Director of New Product Introduction & Programme Management | Leadership |
Chikai Lai | Senior Vice President & Chief Commercial Officer | Leadership |
Alice Clarkson | Global Head of Legal | Leadership |
James Harrison | Group CEO | Leadership |
Simon Baker | Chief People Officer | Leadership |
Debbie Jones | EA To Group CEO / Office & IT Manager | Leadership |
Shweata Dhanuka | Associate Director Commercial Operations | Leadership |
Adriene Jarrell | Director Of Sales, East | Leadership |
Matthew Robinson | Director Planning & Operations | Leadership |
Tony Cates | Director | Board & advisors |
Bill Robinson | Deputy Chairman | Board & advisors |
Duncan Moore | Director | Board & advisors |
Ross Reason | Director | Board & advisors |
David Buckeridge | Non Executive Chairman | Board & advisors |
Alejandra Bruna | Director | Board & advisors |
Noah Sachs | Legal Counsel | Team |
Dave Collier | Sales Specialist | Team |
14 more people are available in the full profile.
Complete people profiles for Cycle Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cycle Pharma
Cycle Pharma has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Applied Therapeutics and Banner Life Sciences.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Drugs for metabolic and cardiovascular diseases are developed. | appliedtherapeutics.com | New York, United States | 2015 | Dec 2025 | •••• | |
Fully integrated product development using its formulation technologies. | bannerls.com | High Point, United States | 1994 | Jan 2025 | •••• |
Complete acquisition details for Cycle Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Cycle Pharma
4 dated milestones of Cycle Pharma across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Cycle Pharma is founded.
- Funding First funding round of $25.0M.
- Acquisition Acquires Banner Life Sciences.
- Acquisition Acquires Applied Therapeutics.
Web traffic of Cycle Pharma
The website of Cycle Pharma (cyclepharma.com) receives about 5.2K visits a month.
- Monthly visits5.2K
▼ 16.5% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cycle Pharma
Complete news archive for Cycle Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cycle Pharma
Cycle Pharma was founded in 2012 and raised its 1st funding round 8 years after it was founded.
Cycle Pharma is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Cycle Pharma has 54 employees.
Annual revenue of Cycle Pharma is $30.23M as on Dec 31, 2020.
Cycle Pharma was founded in 2012 and is based in Cambridge, United Kingdom. Operations focus on biopharmaceutical development, including reformulation and repurposing of small molecule drugs for orphan diseases. FDA approval was granted in August 2017 for NITYR (nitisinone tablets), used to treat Hereditary Tyrosinemia type 1, with a formulation that avoids refrigeration and allows dissolution in water for pediatric use. Generics are also manufactured by the company.
Cycle Pharma offers Cycle Vita and VENXXIVA.
Cycle Pharma has made 2 acquisitions, including Applied Therapeutics, and Banner Life Sciences.
Cycle Pharma has 1 investor. Key investors include Deutsche Bank.
Cycle Pharma operates through Cycle Pharmaceuticals Ltd.